aflibercept
Selected indexed studies
- Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial. (Lancet, 2024) [PMID:38461841]
- Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. (Ophthalmology, 2012) [PMID:23084240]
- Effect of Intravitreal Aflibercept vs Laser Photocoagulation on Treatment Success of Retinopathy of Prematurity: The FIREFLEYE Randomized Clinical Trial. (JAMA, 2022) [PMID:35881122]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Aflibercept, bevacizumab or ranibizumab for diabetic macular oedema: recent clinically relevant findings from DRCR.net Protocol T. (2017) pubmed
- SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB. (2017) pubmed
- Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial. (2024) pubmed
- Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. (2012) pubmed
- Effect of Intravitreal Aflibercept vs Laser Photocoagulation on Treatment Success of Retinopathy of Prematurity: The FIREFLEYE Randomized Clinical Trial. (2022) pubmed
- Evaluation of Intravitreal Aflibercept for the Treatment of Severe Nonproliferative Diabetic Retinopathy: Results From the PANORAMA Randomized Clinical Trial. (2021) pubmed
- Anatomic Outcomes with Faricimab vs Aflibercept in Head-to-Head Dosing Phase of the TENAYA/LUCERNE Trials in Neovascular Age-related Macular Degeneration. (2025) pubmed
- Intravitreal Ziv-Aflibercept: A Comprehensive Review. (2019) pubmed
- Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial. (2016) pubmed
- Aflibercept for Retinopathy of Prematurity: A Systematic Review and Meta-Analysis. (2021) pubmed